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Thursday, October 5, 2017: 12:30 PM Background. The number of patients with coccidioidomycosis continues to increase yearly. Patients with CNS disease require lifelong antifungal therapy due to the high morbidity and mortality of this disease. However, the morbidity and mortality in non-CNS disseminated disease has not been well characterized.
Methods. We conducted a retrospective study of 373 VA-armed forces coccidioidomycosis patients diagnosed between 1955 and 1958 and followed to 1966. Groups were identified as non-disseminated disease, non-CNS disseminated disease with and without multisite dissemination, and disseminated disease to the CNS with and without multisite dissemination. Clinical variables including demographic information, duration and severity of symptoms, coccidioidal serologies, type of infection and complications, time to disseminated disease, and mortality were abstracted from patient charts.
Results. Mortality attributed to coccidioidomycosis in the non-disseminated group was 0.3% (1/297) compared with the non-CNS disseminated group of 8.5% (4/47, median survival 12 months, range 12-24 months, P = 0.0002). Mortality in the CNS disseminated group was 86% (19/22, median survival of 12 months, range 12-156 months, P < 0.0001 compared with non-CNS disseminated). The single site non-CNS disseminated group had a mortality of 4.1% (1/24, survival of 12months) compared with the multiple site non-CNS disseminated group of 13% (3/23, median survival of 18 months, range of 12-24 months, P = 0.57).
Conclusion. This retrospective cohort study demonstrates significant mortality differences between different forms of disseminated coccidioidomycosis. CNS dissemination exhibited the highest mortality rate; however, non-CNS dissemination also exhibited an unacceptably high mortality rate. There was no significant difference in mortality between single site non-CNS disseminated disease and multiple site non-CNS disseminated disease.
Disclosures. All authors: No reported disclosures. Background. Better treatment for HIV has led to the changing epidemiology of cryptococcosis. Important differences in outcomes have recently been demonstrated based on immune status. In this study, we describe the differences in presentation and outcome of cryptococcal infection by immune status in the post-HAART era.
Presentation and Outcome of Cryptococcal Infection Varies by Predisposing
Methods. We conducted a retrospective cohort study of patients diagnosed with cryptococcosis from 2002 through 2014 at our institution. Data included demographics, clinical features, diagnostics, and outcomes. Comparisons were made with χ 2 and one-way ANOVA. Survival analysis was performed with Cox regression with survival censored at 90 days.
Results. We enrolled 243 patients with cryptococcosis: 91 (37.4%) with HIV, 24 (9%) with prior organ transplantation, and 128 (52.6%) with non-HIV non-transplant (NHNT). Age analysis showed HIV patients were younger (40 years) than transplant (53 years) and NHNT (60 years) (P < 0.001). Fevers and headache were more common in HIV (71 and 52%, P = 0.001) than in transplant (33 and 25%, P 0.001) and NHNT (51 and 39%, P 0.001), respectively. Meningitis (71%) was more common in HIV+ than in transplant recipients (45%) or NHNT (43%, P < 0.001). NHNT (37.5%) and transplant (45.8%) had more pulmonary cryptococcosis than HIV (10%, P < 0.001).
Patients with NHNT had a higher risk of mortality (HR 2.642, 95% CI 1.481-4.713) as compared with HIV+. However, transplant recipients with cryptococcosis had risk of 90-day mortality (HR 0.99, 95% CI 0.33-2.99) similar to HIV+ patients.
Conclusion. Cryptococcosis in HIV+ and transplant recipients was less common than in NHNT in our institution and the presentation was different, with meningitis being less prominent. Cryptococcosis in NHNT was associated with higher risk of death than HIV+ patients or transplant recipients. NHNT patients comprise an important group that requires a high degree of clinical suspicion.
Survival curve of 243 patients with cryptococcosis by immune status: blue (NHNT), green (HIV), and red (any transplant). Patients in non-HIV non-transplant cohort had a higher mortality than those with HIV or transplant. Vertical dashes represent censored data (P < .001). Methods. Retrospective study of 534 adult LTR at the Cleveland Clinic (CCF) August 2010-December 2014. We analyzed the association between IMI and risk factors: retransplantation, hemodialysis, reoperation, and fulminant hepatic failure. Model of end-stage liver disease (MELD) was evaluated as novel risk factor. We compared the incidence of IMI among three subgroups: no antifungal prophylaxis, prophylaxis against yeast alone, and prophylaxis against yeast and mold.
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Results. Mean age was 56 ± 11 years. 68% were male (n = 364). The most common underlying diseases were hepatitis C virus (32%), hepatocellular carcinoma (28%), alcoholic cirrhosis (19%), and nonalcoholic steatohepatitis (19%). The overall incidence of IMI was 0.9% (n = 5). The incidence of IMI among LTR with (n = 128) and without (n = 406) risk factors was 0.78 and 0.98%, respectively (see Figure) . Table 1 details the risk factors and outcomes by subgroups. Only one patient with IMI had a risk factor for mold (reoperation). The other four had none. Incidence of IMI among LTR who did not receive antifungal prophylaxis was 1 and 0% in those who received yeast or mold prophylaxis. There was no association between MELD and IMI. Conclusion. Risk factors and MELD did not predict IMI. Because risks are used to recommend mold-active prophylaxis, antifungal agent overuse may be a concern. Additional studies are needed to reconsider risk factors so that transplant providers may target antifungal agents appropriately, practice antifungal stewardship and improve outcomes.
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